Back to results
US 2021/0069147 A1Published application
Pharmaceutical combination and uses thereof
AssigneeBionomics Limited
InventorsGabriel KREMMIDIOTIS, Tina LAVRANOS, Daniel INGLIS
Life of this patent
Estimating the term…
Abstract
The invention relates to pharmaceutical combinations comprising a vascular disrupting agent, in particular the tubulin polymerisation inhibitor BNC105, and an immunotherapeutic agent, in particular an anti-PD-L1, PD-1 or CTLA-4 antibody, and use thereof in the treatment of cancer.
Claims6
(canceled)
(canceled)
A method for treating colon cancer, the method comprising administering to a colon cancer patient in need thereof a vascular disrupting agent and an immunotherapeutic agent,
- wherein the vascular disrupting agent is a tubulin polymerization inhibitor selected from 2-methyl-7-hydroxy-3-(3,4,5-trimethoxybenzoyl)-6-methoxybenzofuran and disodium [6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)-1-benzofuran-7-yl] phosphate,
- wherein the immunotherapeutic agent is an anti-immune-checkpoint inhibitor antibody selected from PD-L1, PD-1, or CTLA-4, and
- wherein the tubulin polymerization inhibitor is administered as a separate dosage form to the immunotherapeutic agent.
6-17. (canceled)
Dependencies are inferred from the claim text.